CD8A and neoplasm: Vorinostat (suberoylanilide hydroxamic acid, SAHA), a class I–II–IV HDACi, was shown to have anti-tumor potential for a 4T1 mammary mice model in which it decreased MDSC accumulation in the spleen, blood, and tumor while promoting the activation and function of CD8+ T cells [96].